CENTRE HOSPITALIER UNIVERSITAIRE DEBESANCON

Their core work

CHU Besançon is a French university hospital that contributes clinical expertise and patient cohorts to European research projects in cardiovascular medicine, neurology, and psychiatry. Their H2020 involvement spans clinical trials for cardiovascular prevention in elderly patients, regenerative stem cell therapy for stroke recovery, lithium treatment optimization for bipolar disorder, and quality-of-life monitoring after cancer immunotherapy. As a hospital-based research centre, they bring real-world clinical settings, patient recruitment capacity, and health economics analysis to multi-partner consortia.

What they specialise in

How they've shifted over time

In the earlier period (2015-2017), CHU Besançon focused on classical clinical medicine — cardiovascular prevention trials with polypills for elderly patients and regenerative stem cell therapy for stroke recovery. In the later period (2018-2024), their focus shifted toward precision medicine and digital health, with projects on biomarker-based prediction of lithium response in psychiatry and digital monitoring of quality of life after immunotherapy. This evolution mirrors the broader clinical research trend from treatment-focused trials toward personalized, data-driven patient care.

CHU Besançon is moving from traditional clinical trials toward biomarker-driven personalized medicine and digital patient monitoring, making them a relevant partner for projects at the intersection of clinical care and health data.

How they like to work

CHU Besançon operates exclusively as a participant or third party — never as a coordinator — which is typical for hospital-based research centres that contribute clinical sites and patient populations rather than leading project management. With 72 unique consortium partners across 16 countries from just 4 projects, they work in large, pan-European clinical consortia. This suggests they are well-integrated into major clinical research networks and comfortable operating within complex multi-site trials.

Despite only 4 projects, CHU Besançon has collaborated with 72 unique partners across 16 countries, reflecting participation in large clinical trial consortia with broad European reach. Their network is concentrated in the health research community with no obvious geographic bias.

What sets them apart

CHU Besançon offers something many research-only institutes cannot: direct access to hospital infrastructure, clinical cohorts, and real-world treatment settings for European health research projects. Their range across cardiovascular, neurological, psychiatric, and oncological research makes them a versatile clinical partner who can recruit patients across multiple therapeutic areas. For consortium builders, they provide the essential hospital-based validation step that translates research into clinical evidence.

Highlights from their portfolio

• SECURE
  Largest funded project (EUR 232,609) — a multi-country clinical trial testing polypill-based cardiovascular prevention in elderly patients, with direct relevance to pharmaceutical and health policy sectors.
• RESSTORE
  Pioneering European trial on stem cell therapy for stroke recovery, combining regenerative medicine with health economics modelling and multimodal MRI — an ambitious translational research effort.
• QUALITOP
  Most recent project (2020-2024) combining cancer immunotherapy with digital quality-of-life monitoring, signalling the hospital's move into digital health and real-world evidence generation.